Recent News

567 News Items found
Media Advisory
A new study offers the first evidence of a drug capable of preventing lethal damage to the gastrointestinal (GI) tract caused by exposure to high levels of ionizing radiation, such as those occurring during a nuclear incident.
Pictured: American Association of Cancer Research Annual Meeting 2012
Announcement
The American Association for Cancer Research (AACR), the world's oldest and largest professional organization dedicated to advancing cancer research, held its 2012 annual meeting in Chicago.
Pictured: Scott Armstrong, Kornelia Polyak & Victor Velculescu
Memorial Sloan Kettering Cancer Center feted three gifted young investigators for their insightful contributions to cancer research in a public symposium on December 1, 2011.
Pictured: Timothy Chan
In the Lab
Two Memorial Sloan Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer.
Pictured: Ion Channel K2P1
Q&A
3D Shape of an Ion Channel Revealed
Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1.
Pictured: Memorial Sloan Kettering logo
In the News
Two of the year's top five cancer research advances cited by the American Society of Clinical Oncology were led by Memorial Sloan Kettering investigators.
Pictured: Eric Pamer
In the Lab
Infections are a common cause of complications in cancer patients. Now a Memorial Sloan Kettering research team finds that a commonly prescribed antibiotic could increase susceptibility to a bacterial infection.
Pictured: Michael Morris
In the Clinic
Researchers at Memorial Sloan Kettering have shown the usefulness of a scale called the Bone Scan Index (BSI) for determining whether some prostate cancer patients are responding to therapy.
Five Memorial Sloan Kettering researchers have been named to Stand Up To Cancer's new Melanoma "Dream Team."
Honors
Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.
Pictured: Structural formula of IBNtxA
In the Lab
Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers.